Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
研究概览
详细说明
This study is a Phase 1 open-label, dose escalation, and cohort expansion study of enoblituzumab administered intravenously (IV) on a weekly schedule for up to 51 doses in combination with IV ipilimumab administered on an every-3-week schedule for 4 doses.
The dose escalation phase is designed to characterize the safety and tolerability of the combination of enoblituzumab and ipilimumab and to define the maximum tolerated or administered dose (MTD/MAD) in patients with B7-H3 expressing mesothelioma, urothelial cancer, NSCLC, SCCHN, Clear cell renal cell carcinoma (ccRCC), ovarian cancer, melanoma, thyroid cancer, Triple negative breast cancer (TNBC), pancreatic cancer, colon cancer, soft tissue sarcoma, or prostate cancer.
The cohort expansion phase, 2 cohorts of 16 patients each will be enrolled to further evaluate the safety and potential efficacy of the combination administered at the MTD/MAD dose in patients with melanoma and NSCLC.
All tumor evaluations will be carried out by both Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related response criteria (irRC).
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Los Angeles、California、美国、90095
- UCLA Hematology-Oncology Clinic
-
-
Connecticut
-
New Haven、Connecticut、美国、06520
- Yale University
-
-
Florida
-
Miami Beach、Florida、美国、33140
- Mount Sinai Medical Center
-
-
Illinois
-
Chicago、Illinois、美国、60637
- University of Chicago
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- Indiana University Simon Cancer Center
-
-
Missouri
-
Saint Louis、Missouri、美国、63110
- Washington University School of Medicine in St. Louis
-
-
New York
-
New York、New York、美国、10032
- Columbia University Medical Center
-
-
Oregon
-
Portland、Oregon、美国、97213
- Providence Portland Medical Center
-
-
Texas
-
Houston、Texas、美国、77030
- Center For Oncology and Blood Disorders
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- University of Wisconsin
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria - Cohort Expansion Phase:
Histologically-proven, unresectable, locally advanced or metastatic melanoma or NSCLC
- Melanoma: Advanced or metastatic melanoma patients may be systemic therapy naïve or may have received systemic treatment for unresectable locally advanced or metastatic disease. A patient who previously received systemic therapy must have had progression on a checkpoint inhibitor (e.g., anti-PD-L1, anti-PD-1, anti-CTLA-4) as the most recent prior therapy.
- NSCLC: NSCLC that has progressed during or following 1 or more prior systemic therapies for unresectable locally advanced or metastatic disease. Patients who are intolerant of, or have refused treatment with standard first line cancer therapy, will be allowed to enroll. Patients must not have had more than 5 prior systemic regimens (excluding experimental therapies) for unresectable locally advanced or metastatic disease.
- B7-H3 expression is not required for eligibility in this study; however, tumor expression of B7-H3 will be evaluated for all patients.
- Measurable disease per RECIST 1.1 criteria
- ECOG performance status 0 or 1
- Acceptable laboratory parameters and adequate organ reserve.
Exclusion Criteria - Cohort Expansion Phase:
- Patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic
- Patients with history of autoimmune disease with certain exceptions
- History of allogeneic bone marrow, stem cell, or solid organ transplant
- Treatment with systemic cancer therapy or investigational therapy within 4 weeks; radiation within 2 weeks; trauma or major surgery within 4 weeks
- History of clinically-significant cardiovascular disease; gastrointestinal perforation; gastrointestinal bleeding, acute pancreatitis or diverticulitis within 4 weeks;
- Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days; positive for human immunodeficiency virus or AIDS, hepatitis B or C.
- Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGA271 or ipilimumab.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:enoblituzumab plus ipilimumab
Enoblituzumab: Fc-optimized, humanized monoclonal antibody.
Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma.
|
enoblituzumab is administered by IV infusion once per week.
Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Number of participants with adverse events
大体时间:1 year
|
Adverse events, serious adverse events
|
1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Peak plasma concentration
大体时间:7 weeks
|
PK of MGA271 in combination with ipilimumab
|
7 weeks
|
Number of participants that develop anti-drug antibodies
大体时间:7 weeks
|
Proportion of patients who develop anti-MGA271 antibodies, immunogenicity
|
7 weeks
|
Change in tumor volume
大体时间:Weeks 9, 18, 27, 39, and 51
|
Anti-tumor activity of MGA271 in combination with ipilimumab using both conventional RECIST 1.1 and immune-related RECIST criteria.
|
Weeks 9, 18, 27, 39, and 51
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
enoblituzumab plus ipilimumab的临床试验
-
Jason J. Luke, MDArray BioPharma主动,不招人
-
Parker Institute for Cancer ImmunotherapyBristol-Myers Squibb; Cancer Research Institute, New York City完全的
-
InBios International, Inc.Biomedical Advanced Research and Development Authority; Fast-Track Drugs & Biologics, LLC完全的
-
Celldex Therapeutics终止
-
Azienda Sanitaria Locale Napoli 2 Nord招聘中
-
Zona Health, IncResearch & Development Concierge Company终止
-
Fondazione Policlinico Universitario Agostino Gemelli...尚未招聘尿路感染 | 输尿管支架相关症状